Role of fibroblast growth factor 21 (fgf21) in the regulation of statural growth

Current Pediatric Reviews

Volumn 11, Issue 2, 2015, Pages 98-105

  Grunwald, Tal ^a   Luca, Francesco De ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bone growth; Catch up growth; FGF21; Growth; Nutrition; Short stature

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COLLAGEN TYPE 10; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GLUCOCORTICOID; GROWTH HORMONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; PARATHYROID HORMONE RELATED PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN TYROSINE KINASE; SEX HORMONE; SMALL INTERFERING RNA; SOMATOMEDIN; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; THYROID HORMONE; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; UNINDEXED DRUG;

ARTICLE; BONE GROWTH; CHONDROGENESIS; FATTY ACID OXIDATION; GLUCONEOGENESIS; GROWTH REGULATION; HORMONE RESISTANCE; HUMAN; KETOGENESIS; MALNUTRITION; METABOLISM; MOLECULAR BIOLOGY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT STATURE; SIGNAL TRANSDUCTION; ANIMAL; BONE DEVELOPMENT; DIET RESTRICTION; INFANT; KNOCKOUT MOUSE; MOUSE; NEWBORN; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; BONE DEVELOPMENT; FASTING; FIBROBLAST GROWTH FACTORS; GROWTH HORMONE; HUMANS; INFANT; INFANT, NEWBORN; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SIGNAL TRANSDUCTION;

EID: 84937141169     PISSN: 15733963     EISSN: 18756336     Source Type: Journal    
DOI: 10.2174/1573396311666150702105152     Document Type: Article

References (107)

1. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 2010; 342(1): 1-11.
2. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27(9): 3417-28.
3. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012; 26(4): 312-24.
4. Gupte J, Yang L, Wu X, et al. The FGFR D3 domain determines receptor selectivity for fibroblast growth factor 21. J Mol Biol 2011; 408(3): 491-502.
5. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008; 22(4): 1006-14.
6. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282(37): 26687-95.
7. Yie J, Hecht R, Patel J, et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 2009; 583(1): 19-24.
8. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 2000; 98(1-2): 115-9.
9. Wu S, Levenson A, Kharitonenkov A, De Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem 2012; 287(31): 26060-7.
10. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149(12): 6018- 27.
11. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115(6): 1627-35.
12. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor- 21. Endocrinology 2007; 148(2): 774-81.
13. Xu J, Stanislaus S, Chinookoswong N, et al. Acute glucoselowering and insulin-sensitizing action of FGF21 in insulinresistant mouse models--association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009; 297(5): E1105-14.
14. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58(1): 250-9.
15. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5(6): 426-37.
16. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5(6): 415-25.
17. Lundasen T, Hunt MC, Nilsson LM, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007; 360(2): 437-40.
18. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alphainducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting J Biol Chem. 2000; 275(37): 28918- 28.
19. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103(11): 1489-98.
20. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 1999; 96(13): 7473-8.
21. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139(2): 456-63.
22. Li X, Fan X, Ren F, et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract. 2011; 93(1): 10-6.
23. Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40(10): 887-92.
24. Chen WW, Li L, Yang GY, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116(1): 65- 8.
25. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32(8): 1542-6.
26. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71(3): 369-75.
27. Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ, et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010; 163(3): 469-77.
28. Matuszek B, Lenart-Lipinska M, Duma D, Solski J, Nowakowski A. Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. Endokrynol Pol 2010; 61(1): 50-4.
29. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53(5): 934-40.
30. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57(5): 1246-53.
31. Badman MK, Kennedy AR, Adams AC, Pissios P, Maratos-Flier E. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. Am J Physiol Endocrinol Metab 2009; 297(5): E1197-204.
32. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59(11): 2781-9.
33. Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 2008; 74(2): 403-12.
34. Kember NF. Cell population kinetics of bone growth: the first ten years of autoradiographic studies with tritiated thymidine. Clin Orthop Relat Res 1971; 76: 213-30.
35. Hunziker EB. Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc Res Tech 1994; 28(6): 505-19.
36. Farnum CE, Wilsman NJ. Cellular turnover at the chondro-osseous junction of growth plate cartilage: analysis by serial sections at the light microscopical level. J Orthop Res 1989; 7(5): 654-66.
37. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335(18): 1363-7.
38. Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003; 349(23): 2211-22.
39. Pantel J, Legendre M, Cabrol S, et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 2006; 116(3): 760-8.
40. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994; 15(3): 369-90.
41. Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology 2001; 142(5): 1685-8.
42. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110(6): 771-81.
43. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82(2): 629-33.
44. Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 2000; 106(9): 1095-103.
45. Isgaard J, Moller C, Isaksson OG, Nilsson A, Mathews LS, Norstedt G. Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone. Endocrinology 1988; 122(4): 1515-20.
46. Schlechter NL, Russell SM, Spencer EM, Nicoll CS. Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc Natl Acad Sci U S A 1986; 83(20): 7932-4.
47. Gafni RI, Weise M, Robrecht DT, et al. Catch-up growth is associated with delayed senescence of the growth plate in rabbits. Pediatr Res 2001; 50(5): 618-23.
48. Silvestrini G, Ballanti P, Patacchioli FR, et al. Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone 2000; 26(1): 33-42.
49. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J Clin Endocrinol Metab 1994; 78(1): 131-7.
50. Crowley S, Hindmarsh PC, Matthews DR, Brook CG. Growth and the growth hormone axis in prepubertal children with asthma J Pediatr. 1995; 126(2): 297-303.
51. Buckler JM, Willgerodt H, Keller E. Growth in thyrotoxicosis. Arch Dis Child 1986; 61(5): 464-71.
52. Leger J, Czernichow P. Congenital hypothyroidism: decreased growth velocity in the first weeks of life. Biol Neonate 1989; 55(4- 5): 218-23.
53. Robson H, Siebler T, Stevens DA, Shalet SM, Williams GR. Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. Endocrinology 2000; 141(10): 3887-97.
54. Kindblom JM, Gothe S, Forrest D, Tornell J, Vennstrom B, Ohlsson C. GH substitution reverses the growth phenotype but not the defective ossification in thyroid hormone receptor alpha 1-/- beta-/- mice. J Endocrinol 2001; 171(1): 15-22.
55. Zachmann M, Prader A, Sobel EH, et al. Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls. J Pediatr 1986; 108(5 Pt 1): 694-7.
56. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000; 13 Suppl 6: 1439-55.
57. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331(16): 1056-61.
58. Cutler GB, Jr. The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 1997; 61(3-6): 141-4.
59. Nilsson O, Chrysis D, Pajulo O, et al. Localization of estrogen receptors-alpha and -beta and androgen receptor in the human growth plate at different pubertal stages. J Endocrinol 2003; 177(2): 319-26.
60. Jansson JO, Eden S, Isaksson O. Sites of action of testosterone and estradiol on longitudinal bone growth. Am J Physiol 1983; 244(2): E135-40.
61. Blanchard O, Tsagris L, Rappaport R, Duval-Beaupere G, Corvol M. Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991; 40(4-6): 711-6.
62. Weise M, De-Levi S, Barnes KM, Gafni RI, Abad V, Baron J. Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci U S A 2001; 98(12): 6871-6.
63. Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M, Smith ER. Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 1993; 76(4): 996-1001.
64. Krohn K, Haffner D, Hugel U, et al. 1,25(OH)2D3 and dihydrotestosterone interact to regulate proliferation and differentiation of epiphyseal chondrocytes. Calcif Tissue Int 2003; 73(4): 400-10.
65. Maor G, Segev Y, Phillip M. Testosterone stimulates insulin-like growth factor-I and insulin-like growth factor-I-receptor gene expression in the mandibular condyle--a model of endochondral ossification. Endocrinology 1999; 140(4): 1901-10.
66. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997; 82(10): 3493-7.
67. Ren SG, Malozowski S, Sanchez P, Sweet DE, Loriaux DL, Cassorla F. Direct administration of testosterone increases rat tibial epiphyseal growth plate width. Acta Endocrinol (Copenh) 1989; 121(3): 401-5.
68. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423(6937): 332-6.
69. Schipani E, Kruse K, Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995; 268(5207): 98-100.
70. Schipani E, Langman CB, Parfitt AM, et al. Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med 1996; 335(10): 708-14.
71. Jobert AS, Zhang P, Couvineau A, et al. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J Clin Invest 1998; 102(1): 34-40.
72. Zhang P, Jobert AS, Couvineau A, Silve C. A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J Clin Endocrinol Metab 1998; 83(9): 3365-8.
73. Lazarus JE, Hegde A, Andrade AC, Nilsson O, Baron J. Fibroblast growth factor expression in the postnatal growth plate. Bone 2007; 40(3): 577-86.
74. Krejci P, Krakow D, Mekikian PB, Wilcox WR. Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage. Pediatr Res 2007; 61(3): 267- 72.
75. Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005; 16(2): 205-13.
76. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007; 370(9582): 162-72.
77. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005; 12(9): 814-21.
78. Rowlinson SW, Yoshizato H, Barclay JL, et al. An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol 2008; 10(6): 740-7.
79. Wilkinson IR, Ferrandis E, Artymiuk PJ, et al. A ligand-receptor fusion of growth hormone forms a dimer and is a potent longacting agonist. Nat Med 2007; 13(9): 1108-13.
80. Lewis UJ, Singh RN, Tutwiler GF, Sigel MB, VanderLaan EF, VanderLaan WP. Human growth hormone: a complex of proteins. Recent Prog Horm Res 1980; 36: 477-508.
81. Argetsinger LS, Campbell GS, Yang X, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 1993; 74(2): 237-44.
82. Van Kerkhof P, Strous GJ. The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. Biochem. Soc. Trans 2001; 29: 488-493.
83. Greenhalgh CJ, Alexander WS. Suppressors of cytokine signaling and regulation of GH action. Growth Horm IGF Res 2004; 14: 200- 206.
84. Rosenfeld RG. The IGF system: new developments relevant to pediatric practice. Endocr Dev 2005; 9: 1-10.
85. LeRoith D. Clinical relevance of systemic and local IGF-I: lessons from animal models. Pediatr Endocrinol Rev 2008; 5 Suppl 2: 739- 43.
86. Graham GG, Adrianzen B, Rabold J, Mellits ED. Later growth of malnourished infants and children. Comparison with 'healthy' siblings and parents. Am J Dis Child 1982; 136(4): 348-52.
87. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15(1): 80-101.
88. Pimstone B, Barbezat G, Hansen JD, Murray P. Growth hormone and protein-calorie malnutrition. Impaired suppression during induced hyperglycaemia. Lancet 1967; 2(7530): 1333-4.
89. Donovan SM, Atilano LC, Hintz RL, Wilson DM, Rosenfeld RG. Differential regulation of the insulin-like growth factors (IGF-I and -II) and IGF binding proteins during malnutrition in the neonatal rat. Endocrinology 1991; 129(1): 149-57.
90. Bucuvalas JC, Horn JA, Chernausek SD. Resistance to growth hormone in children with chronic liver disease. Pediatr Transplant 1997; 1(1): 73-9.
91. Hall K, Hilding A, Thoren M. Determinants of circulating insulinlike growth factor-I. J Endocrinol Invest 1999; 22(5 Suppl): 48-57.
92. Antoniazzi F, Mengarda F, Lauriola S, Serra A, Zamboni G, Tato L. Growth and renal function. Pediatr Med Chir 1997; 19(5): 341- 7.
93. Pugliese MT, Lifshitz F, Grad G, Fort P, Marks-Katz M. Fear of obesity. A cause of short stature and delayed puberty. N Engl J Med 1983; 309(9): 513-8.
94. Hasan TF, Hasan H. Anorexia nervosa: a unified neurological perspective. Int J Med Sci 2011; 8(8): 679-703.
95. Beauloye V, Willems B, de Coninck V, Frank SJ, Edery M, Thissen JP. Impairment of liver GH receptor signaling by fasting. Endocrinology 2002; 143(3): 792-800.
96. Postel-Vinay MC, Cohen-Tanugi E, Charrier J. Growth hormone receptors in rat liver membranes: effects of fasting and refeeding, and correlation with plasma somatomedin activity. Mol Cell Endocrinol 1982; 28: 657-669.
97. Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: regulation by insulin. Endocrinology 1980; 107: 1176-1181.
98. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fastinginduced hormone FGF21. Cell Metab 2008; 8(1): 77-83.
99. Kubicky RA, Wu S, Kharitonenkov A, De Luca F. Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice. Endocrinology 2012; 153(5): 2287- 95.
100. Touvier T, Conte-Auriol F, Briand O, et al. LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. J Clin Invest 2009; 119(12): 3830-8.
101. Wu S, Grunwald T, Khartinonenkov A, Dam J, Jockers R, De Luca F. Increased Expression of Fibroblast Growth Factor 21 (FGF21) during Chronic Undernutrition Causes Growth Hormone Insensitivity in Chondrocytes by Inducing Leptin Receptor Overlapping Transcript (LEPROT) and Leptin Receptor Overlapping Transcriptlike 1 (LEPROTL1) Expression. J Biol Chem 2013; 288: 27375- 27383.
102. Yoon BS, Pogue R, Ovchinnikov DA, et al. BMPs regulate multiple aspects of growth-plate chondrogenesis through opposing actions on FGF pathways. Development 2006; 133: 4667-4678
103. Minina E, Kreschel C, Naski MC, et al. Interaction of FGF, Ihh/PTHrP, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 2002; 3: 439-449.
104. Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab 2010; 95(1): 369-74.
105. Hero M, Dunkel L, Vaaralahti K, Raivio T. Serum FGF21 in boys with idiopathic short stature: relationship to lipid profile, onset of puberty and growth. Clin Endocrinol (Oxf) 2011; 75(1): 141-2.
106. Mericq V, De Luca F, Hernandez MI, et al. Serum Fibroblast Growth Factor 21 Levels Are Inversely Associated with Growth Rates in Infancy. Horm Res Paediatr 2014; 82(5): 324-31.
107. Guasti L, Silvennoinen S, Bulstrode NW, Ferretti P, Sankilampi U, Dunkel L. Elevated FGF21 Leads to Attenuated Postnatal Linear Growth in Preterm Infants Through GH Resistance in Chondrocytes. J Clin Endocrinol Metab 2014; 99(11): E2198-206.